Publications by authors named "Daniel P Rakiec"

9Publications

Distinct Transcriptional Programming Drive Response to MAPK Inhibition in -Mutant Melanoma Patient-Derived Xenografts.

Mol Cancer Ther 2019 12 16;18(12):2421-2432. Epub 2019 Sep 16.

Oncology Drug Discovery, Novartis Institutes for BioMedical Research (NIBR), Cambridge, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-19-0028DOI Listing
December 2019

Hyperactivation of MAPK Signaling Is Deleterious to RAS/RAF-mutant Melanoma.

Mol Cancer Res 2019 01 10;17(1):199-211. Epub 2018 Sep 10.

Oncology, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1541-7786.MCR-18-0327DOI Listing
January 2019

An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide).

Cancer Discov 2013 Sep 10;3(9):1030-43. Epub 2013 Jul 10.

1Oncology Disease Area, 2Department of Oncology Translational Medicine, Novartis Institutes for BioMedical Research, Cambridge; and 3Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://cancerdiscovery.aacrjournals.org/cgi/doi/10.1158/2159
Publisher Site
http://dx.doi.org/10.1158/2159-8290.CD-13-0142DOI Listing
September 2013